Navigation Links
'Two-Faced' Particles Act Like Tiny Submarines
Date:2/29/2008

RALEIGH, N.C., Feb. 29 /PRNewswire-USNewswire/ -- For the first time, researchers at North Carolina State University have demonstrated that microscopic "two-faced" spheres whose halves are physically or chemically different -- so-called Janus particles -- will move like stealthy submarines when an alternating electrical field is applied to liquid surrounding the particles.

A paper describing the research, published in the Feb. 8, 2008, edition of Physical Review Letters, advances knowledge about how potential "smart" materials -- think of tiny engines or sensors -- can move around and respond to changes in their environment. Janus particles could be used as microscopic mixers, molecular "shuttles," self-propelling microsensors or means of targeted drug delivery.

The researchers -- Dr. Orlin Velev, associate professor of chemical and biomolecular engineering at NC State and lead author of the paper; Sumit Gangwal, an NC State graduate student; Dr. Olivier Cayre, a post-doctoral researcher in Velev's lab; and Dr. Martin Bazant from Massachusetts Institute of Technology -- created tiny two-faced gold and plastic particles and applied low frequency alternating current to the water containing the particles. The electric field was of voltage and frequency similar to the ones you'd get if you plugged a device into a socket in your home or office.

Velev says the micrometer-sized particles convert the electrical field into liquid motion around them and then unexpectedly propel themselves perpendicular to the direction of the powered electrodes -- not in the direction of the electrical field, as would be expected. The particles always travel in the same orientation: with the plastic "face" as the front of the mini-submarine and the metallic "face" in the rear, Velev added.

The phenomenon -- called "induced-charge electrophoresis," which had been predicted in a theoretical model by the MIT collaborator -- had not been demonstrated pre
'/>"/>

SOURCE North Carolina State University
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Two-faced miniatures
2. 2-faced particles act like tiny submarines
3. Strengthening fluids with nanoparticles
4. DNA technique yields 3-D crystalline organization of nanoparticles
5. Anthrax vaccine produces immunity with nanoparticles, not needles
6. New DNA-based technique for assembly of nano- and micro-sized particles
7. CeloNova BioSciences Announces Worlds First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres
8. Anthrax vaccine produces immunity with nanoparticles, not needles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... June 1, 2015  Turing Pharmaceuticals AG announced that ... Salinas , MD, MSc,  has joined the company ... Dr. Salinas, who holds a medical degree as ... record of significant accomplishments in the pharmaceutical industry, ... Dr. Salinas has played a leadership role in ...
(Date:6/1/2015)... and YONGIN, South Korea ... great pride that Green Cross Biotherapeutics Inc. (GCBT) kicked ... be located on the Montreal Technoparc,s Saint-Laurent Campus. The ... field investment projects in Canada ... of the first intravenous immunoglobulin (IVIG) and albumin manufacturing ...
(Date:6/1/2015)... , June 1, 2015 ... Decipher® genomic analysis platform, successfully classified various ... genomic expression of certain biomarkers, including one ... Importantly, this unique genomic signature has potential ... to neoadjuvant chemotherapy in patients with muscle-invasive ...
(Date:6/1/2015)... Inc. (TSX-V: BRM) ("Biorem" or "the Company") today announced results for ... first quarter financial statements and MD&A have been filed on SEDAR ... 31,(in CDN$,000 except per share data) , 2015 , ... profit , 1,531 , 329 Ebitda* , ... , (531) Basic earnings (loss) per share ...
Breaking Biology Technology:Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3Green Cross Biotherapeutics Kicks Off Construction in Montreal 2Green Cross Biotherapeutics Kicks Off Construction in Montreal 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 4Biorem Reports Increased Revenues and Earnings for First Quarter 2Biorem Reports Increased Revenues and Earnings for First Quarter 3
... in reconstructive and aesthetic plastic surgeryMEDFORD, Mass., ... growth-stage medical device company developing silk-based biomaterial ... has received 510(k) clearance from the U.S. ... SeriScaffold (TM) silk-based, long term bioresorbable ...
... /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), a vaccine ... the National Institute of Allergy and Infectious Diseases ... in Maryland, USA. The research collaboration involves formulating ... and exploring potential vaccines for HIV and malaria. ...
... its financial results for the year ending 31,December 2008. , , ... process for intravenous iclaprim in US, - Restructuring ... "intravenous-to-oral" Phase II trial with oral, ... - Share placing, Cash and financial investments of CHF ...
Cached Biology Technology:Serica Technologies Receives FDA 510(k) Clearance for SeriScaffold(TM) Technology for Soft Tissue Repair 2Serica Technologies Receives FDA 510(k) Clearance for SeriScaffold(TM) Technology for Soft Tissue Repair 3Serica Technologies Receives FDA 510(k) Clearance for SeriScaffold(TM) Technology for Soft Tissue Repair 4ImmunoVaccine Technologies Signs Agreement with National Institutes of Health to Explore Vaccines for HIV and Malaria 2Arpida Announces Full Year 2008 Financial Results 2Arpida Announces Full Year 2008 Financial Results 3Arpida Announces Full Year 2008 Financial Results 4Arpida Announces Full Year 2008 Financial Results 5
(Date:5/20/2015)... DUBLIN , May 20, 2015 ... Markets ( http://www.researchandmarkets.com/research/h8t4x6/5year ) has announced the ... of the Global Iris Recognition Market" ... http://photos.prnewswire.com/prnh/20130307/600769) , ,This research service analyses ... across the government and commercial sectors, ...
(Date:5/18/2015)... , May 18, 2015 Fingerprint ... sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if ... June until and including Q3 2015 and the sensors will ... . Communicated order values for 2015 hereby amount to 740 ... Q1 2015 of 140 MSEK and a number of smaller ...
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... Genetic disease risk differences between one individual and another are ... the genes themselves, or else differences at the heart of ... By gene regulation we mean the decision that the cell ... activate or suppress the expression of a gene. In theory, ...
... those with HIV have recognized a relationship between how faithfully ... virus is to develop drug resistance. More recently, research has ... and resistance is different for each of the drugs that ... New research conducted by Harvard scientists could help explain ...
... ARBOR, Mich. Scientists have restored the sense of smell ... a hopeful sign for people who can,t smell anything from ... in curing congenital anosmia -- the medical term for lifelong ... other conditions that also stem from problems with the cilia. ...
Cached Biology News:A new light shed on genetic regulation's role in the predisposition to common diseases 2Design help for drug cocktails 2Design help for drug cocktails 3Can't smell anything? This discovery may give you hope 2Can't smell anything? This discovery may give you hope 3
Agarose, low melting/gelling temperature, high MW separation (>1000 bp), 25 g. Suitable for enzymatic modifications. Nuclease-free.Gel point: 24-30 C, EEO (-mr): 300 gm/cm2. Category: Nucleotides &...
Request Info...
Request Info...
Request Info...
Biology Products: